2780 T3D2738 Bleomycin A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. 11056-06-7 5360373 C55H84N17O21S3 White powder. 71°C Soluble Intravenous; systemic absorption is approximately 45%. It has been suggested that bleomycin induces sensitivity to oxygen toxicity and recent studies support the role of the proinflammatory cytokines IL-18 and IL-1beta in the mechanism of bleomycin-induced lung injury. (Wikipedia) In primary pulmonary endothelial cells, bleomycin initiates apoptosis via the extrinsic pathway (A15408). In relation to bleomycin-induced scleroderma, bleomycin exerts various effects on skin-constituted cells such as fibroblasts, keratinocytes, and endothelial cells, as well as immunocytes. Bleomycin upregulates gene expression of ECM proteins as well as fibrogenic cytokines such as TGF-β and CTGF in cultured human skin fibroblasts. Also, in vitro studies showed a dose-dependent stimulation of endothelial cell secretion of collagen synthesis by bleomycin, which was inhibited by the anti-TGF-β antibody. (A15409). Hepatic Route of Elimination: It was reported that patients with moderately severe renal failure excreted less than 20% of the dose in the urine. Half Life: 115 minutes 2B, possibly carcinogenic to humans. (L135) For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas. The most serious complication of bleomycin is pulmonary fibrosis and impaired lung function. (Wikipedia) Bleomycin can also induce scleroderma (A15410, A15408). Excessive exposure may cause fever, chills, nausea, vomiting, mental, confusion, and wheezing. Bleomycin may cause irritation to eyes, skin and respiratory tract. It may also cause a darkening or thickening of the skin. It may cause an allergic reaction. 2009-07-21T20:26:29Z 2014-12-24T20:25:51Z Bleomycin C06854 22907 Bleomycin DB00290 BLM true [H][C@](C)(O)[C@]([H])(N=C(O)[C@@]([H])(C)[C@]([H])(O)[C@@]([H])(C)N=C(O)[C@@]([H])(N=C(O)C1=C(C)C(=N)NC(=N1)[C@]([H])(CC(O)=N)NC[C@]([H])(N)C(O)=N)[C@@]([H])(OC1([H])OC([H])(CO)C([H])(O)C([H])(O)C1([H])OC1([H])OC([H])(CO)C([H])(O)C([H])(OC(O)=N)C1([H])O)C1=CN=CN1)C(O)=NCCC1=NC(=CS1)C1=NC(=CS1)C(O)=NCCC[S+](C)C C55H84N17O21S3 InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29?,30?,34-,35-,36-,37?,38?,39?,40?,41-,42?,43?,53?,54?/m0/s1 InChIKey=OYVAGSVQBOHSSS-WXFSZRTFSA-O 1415.551 1414.518431325 Exogenous Solid HMDB14435 CHEMBL403664 4514492 <p>Hamao Umezawa, Kenji Maeda, Tomohisa Takita, Yuya Nakayama, Akio Fujii, Nobuyoshi Shimada, Hideo Chimura, &#8220;Novel process for producing antibiotics bleomycin.&#8221; U.S. Patent USRE0304514, issued October, 1970.</p>